Alligator Bioscience (ATORX.ST) Stock Price

Alligator Bioscience Price

OMX·CLOSED
0.02
​
Market closed

Revenue at Alligator Bioscience has contracted by 10.7% per year over the past 20 years to 514,000.00 SEK. For Alligator Bioscience, the net margin of -9,990.3% is down versus -1,095.1% a few years ago.

Alligator Bioscience stock price

Access this data via the Eulerpool API

Alligator Bioscience business model & stock analysis

Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody- based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane and currently employs 43 full-time employees. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In the discovery of those drugs, the Company uses its technology platforms ALLIGATOR-GOLD and FIND. ALLIGATOR-GOLD is a library containing human antibodies. FIND (which stands for Fragment Induced Diversity) is an antibody optimization technology. In its pipeline, the Company has thee projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody) and ATOR-1016 (bispecific agonistic antibody), which are in research/preclinical stage.

Frequently asked questions about Alligator Bioscience

7 analysts currently rate the Alligator Bioscience stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect Alligator Bioscience to generate revenue of 5.90 M SEK and earnings per share of -0.01 SEK.

Converted at the current exchange rate, the Alligator Bioscience share trades at 0.00 EUR (0.02 SEK).

The Alligator Bioscience share (ATORX.ST) is listed on 4 stock exchanges, including: London (0RK9.L), Frankfurt (7AL.F), Stockholm (ATORX.ST).

The expected revenue of Alligator Bioscience is 5.90 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Alligator Bioscience is -626,159.67 SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Alligator Bioscience is currently -1.21. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alligator Bioscience stock.

The price-to-sales ratio (P/S) of Alligator Bioscience is currently 0.13. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Alligator Bioscience stock.

The Eulerpool Quality Score for Alligator Bioscience is 2/10.

The ISIN of Alligator Bioscience is SE0024173637. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Alligator Bioscience is A2AN1Z. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Alligator Bioscience is ATORX.ST. The ticker symbol is used to trade Alligator Bioscience shares on the stock exchange.

Fair ValueTerminal
0.01 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
11,953.49 SEK
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Sweden
Currency
SEK
Initial public offering
Nov 23, 2016
ISIN
SE0024173637
Cusip
W0470R106
Sedol
B03HFD5
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-1.21
P/Ee 2027
—
P/S
P/Se
0.13
EV/EBIT
0.15
P/B Ratio
0.02
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-102.68 %
Last updated Oct 9, 2026, 1:22 AM

Alligator Bioscience Ticker

FRANKFURT · 7AL.FLONDON · 0RK9.LSTOCKHOLM · ATORX.STSTOCKHOLM · ATORX.ST